research Effects of 5-alpha reductase inhibitors
5-alpha reductase inhibitors can cause sexual, neurologic, endocrine, and cardiovascular side effects, but these are rare and usually stop after ending treatment.
Search
for
Sort by
Research
450-480 / 1000+ results 
research 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials
Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
research JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.
research Janus kinase inhibitors for alopecia areata: A narrative review
Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.
research Finasteride/spironolactone
research In‐silico Screening of ATP‐competitive Inhibitory Activities of Phytochemicals against Janus Kinase 3 and Its In‐vitro Evaluation
Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.
research 49690 Long-term efficacy of baricitinib in alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2
Baricitinib maintains significant hair regrowth in severe alopecia areata over three years.
research Inhibition of 17α-hydroxylase/C17,20 lyase reduces gating deficits consequent to dopaminergic activation
Blocking CYP17A1 enzyme may help improve certain brain function issues related to dopamine.
research Sorafenib-Associated Facial Acneiform Eruption
Sorafenib can cause facial acne-like eruptions, which improve after reducing the dose or stopping the drug.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research JAK inhibition in the treatment of alopecia areata – a promising new dawn?
JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
research 11β-Hydroxylase inhibitors protect against seizures in mice by increasing endogenous neurosteroid synthesis
11β-Hydroxylase inhibitors help prevent seizures in mice by boosting natural neurosteroid production.
research This Week in JAMA
Early surgery reduces seizure risk in drug-resistant epilepsy; testosterone to DHT conversion doesn't affect muscle anabolism; veterans with PTSD likely to have riskier opioid use; bevacizumab helps in hereditary bleeding disorder.
research Successful treatment of alopecia universalis with abrocitinib: a case report
Abrocitinib may effectively treat stubborn alopecia universalis.
research JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
JAK inhibitors show promise for treating various skin disorders effectively and safely.
research Slow progress in prostate cancer
Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.
research CUTANEOUS SIDE-EFFECTS OF BETA-ADRENERGIC BLOCKERS
Beta-blockers can cause rare skin side-effects, which usually improve after stopping the medication.
research Blood donors on teratogenic drugs and donor deferral periods in a clinical situation
Some blood donors on teratogenic drugs may have unsafe drug levels, suggesting a need for better deferral policies.
research Interaction of antiretroviral medications with finasteride
Antiretrovirals can affect finasteride's effectiveness, so dose adjustments may be needed for men on HIV treatment.
research Finasteride may increase risk of seizures
research Treatment of alopecia areata with JAK inhibitors: a review of the literature
JAK inhibitors can help regrow hair in alopecia areata but have potential long-term risks and require careful monitoring.
research Screening for latent infectious disease in patients with alopecia areata before initiating JAK inhibitors therapy: a single-center real-world retrospective study
Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.
research Cognitive and mood side effects of lower urinary tract medication
Some medications for bladder problems can cause memory issues or mood changes, and doctors should monitor these side effects.
research Scanning electron microscopy of ibrutinib-induced hair shaft changes
research An urticarial drug eruption caused by tofacitinib for alopecia universalis
A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
research 170 Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index
Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.
research Adverse events associated with aromatase inhibitors: an analysis of real-world datasets and drug-gene interaction network
Aromatase inhibitors can cause various adverse reactions, so monitoring is crucial.
research Baricitinib regrows hair in adolescents with alopecia areata
Baricitinib helps regrow hair in teens with severe alopecia areata.
research Ann Robinson’s research reviews —12 May 2022
Self-monitoring blood pressure in pregnant women didn't improve outcomes, diabetes drugs may increase gallbladder disease risk, a new drug helps severe hair loss, a plant-based COVID-19 vaccine is 69.5% effective, and new anticoagulants are safer for diabetics with heart rhythm issues than warfarin.
research NEW PROPRIETARY BRANDS: Cefaclor monohydrate
Lifestyle changes are more effective than medication for reducing type 2 diabetes risk.